Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1702-1708

  Dresemann, G ^a  

^a Franz Hospital   (Germany)

Author keywords

Efficacy; Glioblastoma multiforme; Hydroxyurea; Imatinib; PDGFRs; Safety

Indexed keywords

HYDROXYUREA; IMATINIB; NIMUSTINE; NITROSOUREA; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; EDEMA; FEMALE; GLIOBLASTOMA; HUMAN; LUNG EMBOLISM; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE;

EID: 26444621412     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi317     Document Type: Article

References (50)

1. Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA 2000; 97: 6242-6244.
2. Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trial. J Clin Oncol 1999; 17: 2572.
5. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors, Part 1: Growth factor and ras signaling pathways. Expert Rev Anticancer Ther 2003; 3: 595-614.
6. Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-4553.
7. Lokker NA, Sullivan CM, Hollenbach SJ et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62: 3729-3735.
8. Shih AH, Dai C, Hu X et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783-4789.
9. Uhrbom L, Hesselager G, Nister M et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retro-virus. Cancer Res 1998; 58: 5275-5279.
10. Dai C, Celestino JC, Okada Y et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-1925.
11. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003; 22: 722-733.
12. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-3219.
13. George D. Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 2001; 28 (5 Suppl 17): 27-33.
14. Strawn LM, Mann E, Elliger SS et al. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 1994; 269: 21215-21222.
15. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004; 31 (2 Suppl 6): 18-23.
16. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-5484.
17. Plate KH, Breier G, Farrell CL, Risau W et al. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992; 67: 529-534.
18. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
19. Buchdunger E, Zimmerman J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
20. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
21. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
22. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
23. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
24. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
25. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Min 2002; 97 (Suppl 1): 28-30.
26. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-S71 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Ent J Cancer 2003; 39: 2006-2011.
27. Raymond E, Brandes A, van Oosterom A et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC:NDDG/BTG Intergroup Study. J Clin Oncol 2004; 22 (14S Suppl): 107 (Abstr 1501).
28. Wen PY, Yung WK, Hess K et al. Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08). Proc Am Soc Clin Oncol 2002; 21: 73a (Abstr 288).
29. Rich IN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133-142.
30. Holdholf M, Kreuzer KA, Appett C et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
31. O'Reilly T, Wartmann M, Maira SM et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2004; 55: 307-317.
32. Katayama R, Huelsmeyer Mk, Marr AK et al. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004; 54: 25-33.
33. Aloyz R, Grzywacz K, Xu ZY et al. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004; 18: 409-414.
34. Kano Y, Akutsu M, Tsunoda S et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
35. Dogruel M, Gibbs JE, Thomas SA. Hydroxyurea transport across the blood-bmin and blood-cerebrospinal fluid barriers of the guinea-pig. J Neurochem 2003; 87: 76-84.
36. Gwilt PR, Manouilov M, McNabb et al. Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. J Clin Pharmacol 2003; 43: 1003-1007.
37. Goldman CK, Kim J, Wong WL et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4: 121-133.
38. Levi AD, Wallace MC, Bernstein M, Walter BC et al. Venous thromboembolism after brain tumor surgery: A retrospective review. Nemosurgery 1991; 28: 859-863.
39. Cheruku R, Tapazoglou E, Ensley J et al. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991; 68: 2621-2624.
40. Stupp R, Mason WP, van den Bent MJ et al. Concomitiant and adjuvant temozolomide (TMZ) and radiotherapy for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2004; 22 (14S Suppl): 107 (Abstr 2).
41. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
42. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter phase II trial of temozolonuide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-266.
43. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005; 25: 1-7.
44. Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study. Neurology 1996; 47: 684-690.
45. Ozvegy-Laczka C, Hegedus T, Varady G et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495.
46. Illmer T, Schaich M, Platzbecker U et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408.
47. Houghton PJ, Germain GS, Harwood FC et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-2337.
48. Cuha A, Dashner K, Black PM et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995; 60: 168-173.
49. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokme Growth Factor Rev 2004; 15: 275-286.
50. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A et al. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-443.